Data Collection
For each patient, demographic and laboratory data including past medical and drug history, outcomes, baseline complete blood count and inflammatory markers including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), ferritin and lactate dehydrogenase (LDH), and liver function tests were recorded. Also, vital signs on admission and selected pharmacotherapy for management of COVID-19 besides, the administration of atorvastatin and other cardiovascular medications including Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin Receptor Blockers (ARBs), and beta-blockers, were documented. Atorvastatin use was defined as the administration of the medication on 1st day of admission.